Vor Biopharma (NASDAQ:VOR) Director Sells $7,666,646.01 in Stock

Key Points

• Vor Biopharma Director Ra Capital Management, L.P. sold 260,859 shares for a total of $7,666,646.01, marking a 94.53% decrease in ownership.
• The company's stock has experienced significant volatility, with a twelve-month low of $2.62 and a high of $65.80, currently trading at $29.00.
• Equity analysts have mixed views on Vor Biopharma, with ratings ranging from "strong sell" to "outperform" and a consensus target price of $77.83.

Vor Biopharma Inc. (NASDAQ:VOR - Get Free Report) Director Ra Capital Management, L.P. sold 260,859 shares of the stock in a transaction dated Friday, October 17th. The stock was sold at an average price of $29.39, for a total value of $7,666,646.01. Following the transaction, the director owned 15,104 shares in the company, valued at $443,906.56. This trade represents a 94.53% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Thursday, October 16th, Ra Capital Management, L.P. sold 151,803 shares of Vor Biopharma stock. The shares were sold at an average price of $29.45, for a total value of $4,470,598.35.
• On Wednesday, October 15th, Ra Capital Management, L.P. sold 51,363 shares of Vor Biopharma stock. The stock was sold at an average price of $30.55, for a total value of $1,569,139.65.

Vor Biopharma Stock Performance

Shares of VOR traded down $0.06 during trading on Friday, reaching $29.00. The company's stock had a trading volume of 613,740 shares, compared to its average volume of 395,121. Vor Biopharma Inc. has a twelve month low of $2.62 and a twelve month high of $65.80. The business's fifty day moving average price is $36.55. The company has a market cap of $198.65 million, a P/E ratio of -0.11 and a beta of 2.07.

Vor Biopharma (NASDAQ:VOR - Get Free Report) last released its quarterly earnings data on Tuesday, August 12th. The company reported ($43.60) earnings per share for the quarter, missing the consensus estimate of ($11.40) by ($32.20).

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on VOR shares. Zacks Research cut shares of Vor Biopharma from a "hold" rating to a "strong sell" rating in a report on Monday. Robert W. Baird raised shares of Vor Biopharma from a "neutral" rating to an "outperform" rating and upped their target price for the stock from $20.00 to $64.00 in a research note on Wednesday. Wedbush reissued an "outperform" rating on shares of Vor Biopharma in a research report on Thursday, June 26th. Weiss Ratings reissued a "sell (d-)" rating on shares of Vor Biopharma in a report on Wednesday, October 8th. Finally, HC Wainwright restated a "buy" rating and set a $60.00 price target on shares of Vor Biopharma in a research note on Thursday, August 14th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, three have issued a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus target price of $77.83.

Institutional Trading of Vor Biopharma

A number of hedge funds have recently made changes to their positions in the stock. Money Concepts Capital Corp boosted its holdings in Vor Biopharma by 106.1% in the first quarter. Money Concepts Capital Corp now owns 51,535 shares of the company's stock worth $37,000 after purchasing an additional 26,535 shares during the last quarter. Goldman Sachs Group Inc. increased its holdings in Vor Biopharma by 218.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company's stock valued at $61,000 after acquiring an additional 58,247 shares during the last quarter. XTX Topco Ltd purchased a new position in Vor Biopharma during the 2nd quarter valued at approximately $66,000. OMERS ADMINISTRATION Corp purchased a new stake in Vor Biopharma during the first quarter valued at $100,000. Finally, Jane Street Group LLC bought a new position in shares of Vor Biopharma in the 1st quarter valued at about $140,000. 97.29% of the stock is owned by institutional investors.

About Vor Biopharma

Vor Biopharma, Inc, a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.